Ranbaxy Of India, Merck Of U.S. End Drug-Discovery Agreement
This article was originally published in PharmAsia News
Executive Summary
India's Ranbaxy Laboratories and U.S.-based Merck have ended a collaboration aimed at discovering and developing new drugs, as reported in PharmAsia News, Dec. 15
|
India's Ranbaxy Laboratories and U.S.-based Merck have ended a collaboration aimed at discovering and developing new drugs, as reported in (Also see "Ranbaxy's Loss Is Dr. Reddy's Gain As Merck Shifts R&D Project For Anti-infectives" - Scrip, 15 Dec, 2010.). The two firms had intended, when they signed the pact in 2008, to develop anti-bacterial and anti-fungal drugs. That agreement was to have lasted for five years, to 2013. The companies would not elaborate on the cancellation of the agreement. Under the plan, Ranbaxy was to receive an up-front payment, plus milestone and royalty payments. (Click here for more - a subscription may be required) "Ranbaxy: Have Discontinued Drug Discovery Pact With Merck" - Nikkei (Japan) (1/6/11) |